Search Results

hC Bioscience today announced preclinical data supporting its lead program in severe hemophilia A at the World Federation of Hemophilia 2024 World Congress in Madrid, Spain.

The approval makes Pfizer’s Hympavzi the first once-weekly subcutaneous prophylactic injection for hemophilia B in the U.S., according to the company, which is currently embroiled in a row with activist investor Starboard Value.

Sangamo and Pfizer’s hemophilia A gene therapy candidate scored a Phase III victory last week. However, with the genomic medicine company soon to run out of cash, Sangamo’s short-term prospects look bleak but not unsalvageable, analysts say.

TiumBio Co., Ltd. announced today that the company presented clinical outcomes of its hemophilia treatment, TU7710, at the 32nd Congress of the International Society on Thrombosis and Haemostasis (ISTH) and embarked on building new global partnerships.

Be Biopharma, Inc. (“Be Bio”), a company pioneering the discovery and development of Engineered B Cell Medicines (BCMs), today announced the clearance of its Investigational New Drug application (IND) from the U.S. Food and Drug Administration (FDA) for BE-101, a first-in-class BCM in development for the potential treatment of hemophilia B.

Christian Attar Law Firm and Freedman Normand Friedland LLP, in conjunction with forensic investigators, have uncovered evidence of a potential multi-year market manipulation scheme that has caused substantial damages to the Company and its shareholders